Date: 2011-03-15
Type of information: Services contract
Compound: Phosphoscout
Company: KINAXO Biotechnologies (Germany) Takeda Pharmaceutical (Japan)
Therapeutic area:
Type agreement: services
Action mechanism: phosphoproteomics technology
Disease:
Details: Kinaxo Biotechnologies has entered a second collaboration with Takeda Pharmaceutical. The previous one has been concluded in April 2008. Under the new agreement Kinaxo will continue to apply its quantitative phosphoproteomics technology PhosphoScout® to assist in research of drugs under development at Takeda. This technology combines proprietary chemical proteomics technologies with mass spectrometry to identify and characterize a drug candidate's native molecular targets in cell lines and tissue samples. It enables quantitative analysis of cellular phosphoproteomes on a global scale and can identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug response biomarkers in clinical trials. This will allow Takeda to take early educated decisions on drug efficacy and safety.
Financial terms: Financial details of the agreement were not disclosed.
Latest news: Last month, Evotec has signed a definitive agreement to acquire all shares in Kinaxo Biotechnologies.
